An Verrijken

Mrs. An Verrijken


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
PLPhilippe Lefebvre
Philippe Lefebvre
FLFanny Lalloyer
Fanny Lalloyer
EBEric Baugé
Eric Baugé
MPMichal Pawlak
Michal Pawlak
CGCéline Gheeraert
Céline Gheeraert
BSBart Staels
Bart Staels
Nonalcoholic fatty liver disease prevalence is soaring with the obesity pandemic, but the pathogenic mechanisms leading to the progression toward active nonalcoholic steatohepatitis (NASH) and fibrosis, major causes of liver-related death, are poorly defined. To identify key components during the progression toward NASH and fibrosis, we investigated the liver transcriptome in a human cohort of NASH patients. The transition from histologically proven fatty liver to NASH and fibrosis was characterized by gene expression patterns that successively reflected altered functions in metabolism, inflammation, and epithelial-mesenchymal transition. A meta-analysis combining our and public human transcriptomic datasets with murine models of NASH and fibrosis defined a molecular signature characterizing NASH and fibrosis and evidencing abnormal inflammation and extracellular matrix (ECM) homeostasis. Dermatopontin expression was found increased in fibrosis, and reversal of fibrosis after gastric bypass correlated with decreased dermatopontin expression. Functional studies in mice identified an active role for dermatopontin in collagen deposition and fibrosis. PPARα activation lowered dermatopontin expression through a transrepressive mechanism affecting the Klf6/TGFβ1 pathway. Liver fibrotic histological damages are thus characterized by the deregulated expression of a restricted set of inflammation- and ECM-related genes. Among them, dermatopontin may be a valuable target to reverse the hepatic fibrotic process.

19 March 2024 in Gastroenterology
Verified
Journal Article
Open access
LKLaurens A. van Kleef
Laurens A. van Kleef
SFSven M Francque
Sven M Francque
JPJhon E. Prieto-Ortiz
Jhon E. Prieto-Ortiz
MSMilan J Sonneveld
Milan J Sonneveld
CSCarlos B. Sanchez-Luque
Carlos B. Sanchez-Luque
WBWillem Pieter Brouwer
Willem Pieter Brouwer
There is an unmet need for non-invasive tests to improve case-finding and aid primary care professionals in referring patients at high risk of liver disease. A metabolic dysfunction-associated fibrosis (MAF-5) score was developed and externally validated in a total of 21,797 individuals with metabolic dysfunction, in population-based (NHANES2017-2020, NHANESIII, Rotterdam Study) as well as hospital-based cohorts (from Antwerp and Bogota). Fibrosis was defined as liver stiffness (LSM)≥8.0kPa. Diagnostic accuracy was compared to FIB-4, NFS and SAFE. MAF-5 was externally validated with LSM≥8.0kPa, with shear-wave elastography (SWE≥7.5 kPa) and biopsy-proven steatotic liver disease according to METAVIR and NASH-CRN scores, and was tested for prognostic performance (all-cause mortality). The MAF-5 score comprised waist circumference, BMI, diabetes, AST and platelets. With this score, 60.9% was predicted at low, 14.1% at intermediate and 24.9% at high risk of fibrosis. The observed prevalence was 3.3%, 7.9% and 28.1%, respectively. The AUROC of MAF-5 (0.81) was significantly higher than FIB-4 (0.61), and outperformed the FIB-4 among the young (NPV 99% [AUC 0.86] versus 94% [AUC 0.51]) and elderly (NPV 94% [AUC 0.75] versus 88% [AUC 0.55]). MAF-5 showed excellent performance to detect LSM≥12kPa (AUC 0.86 training, AUC 0.85 validation) and good performance in detecting liver stiffness and biopsy-proven liver fibrosis among the external validation cohorts. MAF-5 score>1 was associated with increased risk of all-cause mortality in (un)adjusted models (aHR:1.59, 95%CI:1.47-1.73). The MAF-5 score is a validated, age-independent, inexpensive referral tool to identify individuals at high risk of liver fibrosis and all-cause mortality in primary care populations, using simple variables.

1 March 2018 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
AMAbraham S. Meijnikman
Abraham S. Meijnikman
Christophe De BlockChristophe De Block
Christophe De Block
AVAn Verrijken
An Verrijken
IMIlse Mertens
Ilse Mertens
LGLuc F. Van Gaal
Luc F. Van Gaal
The aim of this study to compare the diagnostic accuracy of the metabolic syndrome (MetS) with the FINDRISC score to screen for type 2 diabetes mellitus T2DM in an overweight/obese population. Subjects 18 years or older visiting the obesity clinic of the Antwerp University Hospital were consecutively recruited between 2012 and 2014. Every patient underwent a standard metabolic work-up including a clinical examination with anthropometry. Glucose status was tested using OGTT and Hba1c. FINDRISC questionnaire and MetS were examined. Of 651 subjects, 50.4% were diagnosed with prediabetes, whereas 11.1% was diagnosed with T2DM. FINDRISC score increased with worsening of glucose status 11 ± 3, 13 ± 4 and 15 ± 5 in respectively, subjects without T2DM, prediabetes and T2DM. 312 subjects had the MetS. The aROC of the FINDRISC to identify subjects with T2DM was 0.76 (95% CI 0.72–0.82), sensitivity was 64% and specificity was 63% with 13 as cutoff point. Adding FPG or HbA1c to FINDRISC, the aROC increased significantly to 0.91(95% CI 0.88–0.95) and 0.93(95% CI 0.90–0.97), respectively (p < 0.001). The aROC of the MetS to identify subjects with diabetes was 0.72 (95% CI 0.65–0.78), sensitivity was 75% and specificity was 55%. The aROC of the FINDRISC + HbA1c was significantly higher than the MetS for predicting T2DM (p < 0.001). Prediction of type 2 diabetes is important for timely intervention and to avoid chronic complications associated with the disease. Our findings suggest, that it may be of good clinical practice to use the FINDRISC score + HbA1c in a two-step screening model for diabetes rather than using the metabolic syndrome.

13 August 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SDSara Diels
Sara Diels
Bart CuypersBart Cuypers
Bart Cuypers
ATAsta Tvarijonaviciute
Asta Tvarijonaviciute
BDBruno Derudas
Bruno Derudas
EDEvelien Van Dijck
Evelien Van Dijck
WHWim Van Hul
Wim Van Hul
Background: The multifactorial nature of non-alcoholic fatty liver disease cannot be explained solely by genetic factors. Recent evidence revealed that DNA methylation changes take place at proximal promoters within susceptibility genes. This emphasizes the need for integrating multiple data types to provide a better understanding of the disease’s pathogenesis. One such candidate gene is paraoxonase-1 (PON1). Substantial interindividual differences in PON1 are apparent and could influence disease risk later in life. The aim of this study was therefore to determine the different regulatory aspects of PON1 variability and to examine them in relation to the predisposition to obesity-associated fatty liver disease. Results: A targeted multi-omics approach was applied to investigate the interplay between PON1 genetic variants, promoter methylation, expression profile and enzymatic activity in an adult patient cohort with extensive metabolic and hepatic characterisation including liver biopsy. Alterations in PON1 status were shown to correlate with waist-to-hip ratio and relevant features of liver pathology. Particularly, the regulatory polymorphism rs705379:C > T was strongly associated with more severe liver disease. Multivariable data analysis furthermore indicated a significant association of combined genetic and epigenetic PON1 regulation. This identified relationship postulates a role for DNA methylation as a mediator between PON1 genetics and expression, which is believed to further influence liver disease progression via modifications in PON1 catalytic efficiency. Conclusions: Our findings demonstrate that vertical data-integration of genetic and epigenetic regulatory mechanisms generated a more in-depth understanding of the molecular basis underlying the development of obesity-associated fatty liver disease. We gained novel insights into how NAFLD classification and outcome are orchestrated, which could not have been obtained by exclusively considering genetic variation.

27 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
EDEvelien Van Dijck
Evelien Van Dijck
SBSigri Beckers
Sigri Beckers
SDSara Diels
Sara Diels
THTammy Huybrechts
Tammy Huybrechts
AVAn Verrijken
An Verrijken
WHWim Van Hul
Wim Van Hul
Recently, it was reported that heterozygous PCSK1 variants, causing partial PC1/3 deficiency, result in a significant increased risk for obesity. This effect was almost exclusively generated by the rare p.Y181H (rs145592525, GRCh38.p13 NM_000439.5:c.541T>C) variant, which affects PC1/3 maturation but not enzymatic capacity. As most of the identified individuals with the heterozygous p.Y181H variant were of Belgian origin, we performed a follow-up study in a population of 481 children and adolescents with obesity, and 486 lean individuals. We identified three obese (0.62%) and four lean (0.82%) p.Y181H carriers (p = 0.506) through sanger sequencing and high resulting melting curve analysis, indicating no association with obesity. Haplotype analysis was performed in 13 p.Y181H carriers, 20 non-carriers (10 with obesity and 10 lean), and two p.Y181H families, and showed identical haplotypes for all heterozygous carriers (p < 0.001). Likewise, state-of-the-art literature concerning the role of rare heterozygous PCSK1 variants implies them to be rarely associated with monogenic obesity, as first-degree carrier relatives of patients with PC1/3 deficiency are mostly not reported to be obese. Furthermore, recent meta-analyses have only indicated a robust association for scarce disruptive heterozygous PCSK1 variants with obesity, while clinical significance is less or sometimes lacking for most nonsynonymous variants.

27 November 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
WVWim Verlinden
Wim Verlinden
EMEugénie Van Mieghem
Eugénie Van Mieghem
LDLaura Depauw
Laura Depauw
TVThomas Vanwolleghem
Thomas Vanwolleghem
LVLuisa Vonghia
Luisa Vonghia
SFSven M Francque
Sven M Francque
The incidence of non-alcoholic fatty liver disease (NAFLD) is rising across the globe, with the presence of steatohepatitis leading to a more aggressive clinical course. Currently, the diagnosis of non-alcoholic steatohepatitis (NASH) is based on histology, though with the high prevalence of NAFLD, a non-invasive method is needed. The 13C-aminopyrine breath test (ABT) evaluates the microsomal liver function and could be a potential candidate. We aimed to evaluate a potential change in liver function in NASH patients and to evaluate the diagnostic power of ABT to detect NASH. We performed a retrospective analysis on patients suspected of NAFLD who underwent a liver biopsy and ABT. 440 patients were included. ABT did not decrease in patients with isolated liver steatosis but decreased significantly in the presence of NASH without fibrosis and decreased even further with the presence of significant fibrosis. The predictive power of ABT as a single test for NASH was low but improved in combination with ALT and ultrasonographic steatosis. We conclude that microsomal liver function of patients with NASH is significantly decreased, even in the absence of fibrosis. The ABT is thus a valuable tool in assessing the presence of NASH; and could be used as a supplementary diagnostic tool in clinical practice.